ProSphere™ Printing Based Polymer Microsphere Platform for Sustained-Release Vaccine
As the leading CRO in the vaccine field, Creative Biolabs has expanded its business into all aspects of vaccine development. In addition to proficiency in the design and evaluation of vaccines for all types, diseases, and pathogens, we also have advanced and extensive experience in vaccine delivery and formulation design.
Sustained Release Vaccine
Conventional vaccines often require repeated injections over long periods of time, resulting in poor patient compliance. Therefore, a single-dose sustained-release vaccine that can achieve or exceed multiple injections in a single injection is one of the research hotspots in the field of vaccines. The sustained-release vaccine delivery system has advantages like reducing the number of administrations, improving patient compliance, enhancing and prolonging the humoral immune response, increasing the intensity of cellular immune response, facilitating the generation of immunological memory reactions, and not causing serious inflammatory reactions. The sustained release vaccine delivery system has aluminum adjuvant, complete Freund's adjuvant, incomplete Freund's adjuvant, high molecular polymer microspheres, gel preparation, sustained release stent and implant, etc. Their common feature is the drug reservoir function, which continuously stimulates the body to produce an immune response by slowly releasing antigen or adjuvant. The sustained release system with different release behavior can be prepared by adjusting the degree of polymerization of the material, relative molecular mass, particle size, and void ratio, drug loading, material ratio or preparation conditions.
ProSphere™ - Outstanding Extended Sustained-Release Platform for Prolonged Antigen Release
In the past three decades, reactor-based polymer microencapsulation emulsion technology has been used in 95% of the market. This technology requires a large infrastructure, a large amount of environmentally unfriendly organic solvents and it is inefficient and can produce many useless particles. Creative Biolabs has developed a sustained-release platform, ProSphere™, using printing technology to produce millions of microspheres per second on a limited infrastructure with easy-to-remove environmentally friendly solvents. Most importantly, due to the production under identical controlled conditions, the microspheres produced by the platform are monodisperse and homogenous, which makes the vaccine have superior clinical profile and injection performance.
Advantages of ProSphere™ Platform
- Precise, environment-friendly, scalable, resource-saving and efficient
- Reduced timeline for production
- Ensured monodispersed microparticles, lower variability
- Ability to release vaccines in a linear tightly controlled and predictable manner over an extended time as long as 6 months
- Avoiding dose dumping and burst
- Lessen injection site pain
- Compatible with much smaller gauge needles
Using state-of-the-art printing technology, Creative Biolabs' ProSphere™ platform delivers efficient and uniform microsphere production. Its superior vaccine release performance greatly enhances the vaccine's effectiveness, improves compliance of vaccinators, and is confirmed in multiple vaccines. ProSphere™ has proven to be superior in extending the duration of vaccine release, enhancing vaccine efficacy, and having excellent commercial production characteristics.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
